SCHEMBL6232375

SCHEMBL6232375

O=C(Nc1cccc(Cl)c1)c1[c]ccc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
FADS1 O60427 2/20 0.51
GRM4 Q14833 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
MAOB P27338 3/20 0.51
HIF1A Q16665 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.50
HTT P42858 2/20 0.50
ALDH1A1 P00352 1/20 0.50
KCNK3 O14649 1/20 0.49
KCNK9 Q9NPC2 1/20 0.49
GRM5 P41594 1/20 0.48
P2RX1 P51575 1/20 0.48
P2RX4 Q99571 1/20 0.48
P2RX7 Q99572 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15778699 0.80 FADS1 (0.68) NPC1RAB9AFADS1GRM4HDAC6
SCHEMBL6228430 0.78 FKBP5 (0.53) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL6228359 0.76 NPC1 (0.49) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL9407432 0.76 FADS1 (0.58) NPC1RAB9AFADS1GRM4HDAC6
SCHEMBL4620777 0.74 NPC1 (0.63) NPC1RAB9AFADS1GRM4HDAC6
SCHEMBL7976244 0.73 GAA (0.45) NPC1RAB9AHIF1AMEN1KMT2A
SCHEMBL9106594 0.73 PLK1 (0.54) NPC1RAB9AHIF1AALDH1A1
SCHEMBL6232372 0.71 NPC1 (0.69) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL3794687 0.71 NPC1 (1.00) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL9298921 0.71 NR4A1 (0.38) MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900219-B2 ABCA-1 elevating compounds CV THERAPEUTICS, INC. (US) 2005-05-31 US disclosed
EP-1513534-A2 COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2005-03-16 EP disclosed
US-20030220356-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2003-11-27 US disclosed
WO-2003084544-A2 COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220356-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 NPC1 6/4885RAB9A 2138/4885FADS1 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.